Evidence map›Paper›PMID 29285689›Full record

ReviewClinical journal of gastroenterology2018

Gut microbiota in the pathogenesis of inflammatory bowel disease.

Atsushi Nishida, Ryo Inoue, Osamu Inatomi, Shigeki Bamba, Yuji Naito, Akira Andoh

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Clinical journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 760 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
760citing papers in PubMed, 7 pooled it
26.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03589183 recruitingnot on this map

Discovery of Gut Microbial Signatures in Inflammatory Bowel Disease

TypeobservationalSponsorKyunghee University Medical CenterRan2018 to 2028Enrolled1,500ConditionsInflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
NCT05318365 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Bladder and Bowel Dysfunction in Children

TypeinterventionalSponsorUniversity of AarhusRan2022 to 2025Enrolled100ConditionsBladder and Bowel DysfunctionArmsPolyethylene Glycol 3350, Urotherapy
3 · Its place in the literature

Who cites it

760 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,353 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. NontoxigenicMicroorganisms · 2026
    Review
  16. Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
  17. Article
  18. Article
  19. Review
  20. Review

700 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Atsushi NishidaDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan. atsuda@belle.shiga-med.ac.jp.ORCID http://orcid.org/0000-0002-1288-3272
Ryo InoueLaboratory of Animal Science, Department of Agriculture and Life Science, Kyoto Prefectural University, Kyoto, 606-8522, Japan.
Osamu InatomiDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.
Shigeki BambaDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.
Yuji NaitoDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.
Akira AndohDepartment of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.
Shiga University of Medical Science · JPKyoto Prefectural University · JPKyoto Prefectural University of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a chronic and relapsing inflammatory disorder of the intestine. Although its incidence is increasing globally, the precise etiology remains unclear and a cure for IBD has yet to be discovered. The most accepted hypothesis of IBD pathogenesis is that complex interactions between genetics, environmental factors, and the host immune system lead to aberrant immune responses and chronic intestinal inflammation. The human gut harbors a complex and abundant aggregation of microbes, collectively referred to as the gut microbiota. The gut microbiota has physiological functions associated with nutrition, the immune system, and defense of the host. Recent advances in next-generation sequencing technology have identified alteration of the composition and function of the gut microbiota, which is referred to as dysbiosis, in IBD. Clinical and experimental data suggest dysbiosis may play a pivotal role in the pathogenesis of IBD. This review is focused on the physiological function of the gut microbiota and the association between the gut microbiota and pathogenesis in IBD. In addition, we review the therapeutic options for manipulating the altered gut microbiota, such as probiotics and fecal microbiota transplantation.

Indexed as

Fecal Microbiota TransplantationGastrointestinal MicrobiomeHumansImmunity, InnateInflammatory Bowel DiseasesNutritional Physiological PhenomenaProbioticsDysbiosisFecal microbiota transplantationInflammatory bowel diseaseMicrobiota

Identifiers

PMID29285689
OpenAlexW2778416039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.